# A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

> **NCT00253201** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 636 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia

## Interventions

- **DRUG:** galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00253201
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1997-10
- **Target enrollment:** 636 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253201, "A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00253201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*